{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:37:12Z","timestamp":1794278232240,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"La Roche (F. Hoffmann-La Roche Ltd)","id":[{"id":"https:\/\/ror.org\/00by1q217","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41591-025-03734-3","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:01:55Z","timestamp":1749013315000},"page":"2746-2754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Mar\u00eda","family":"Gion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6615","authenticated-orcid":false,"given":"Isabel","family":"Blancas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cortez-Castedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-7583","authenticated-orcid":false,"given":"Alfonso","family":"Cort\u00e9s-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-3367","authenticated-orcid":false,"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-4193","authenticated-orcid":false,"given":"Seraf\u00edn","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Calvo-Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mart\u00ednez-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiz-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisenda","family":"Llabr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Taberner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1572","authenticated-orcid":false,"given":"Michelino","family":"de Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garc\u00eda-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rodr\u00edguez-Morat\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-8293","authenticated-orcid":false,"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of ATRACTIB Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"3734_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer 8, 95 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"3734_CR2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495 (2021).","journal-title":"Ann. Oncol."},{"key":"3734_CR3","unstructured":"Surveillance Research Program, National Cancer Institute. SEER*Explorer: An Interactive Website for SEER Cancer Statistics (SEER Incidence Data, November 2024, accessed 16 May 2025); https:\/\/seer.cancer.gov\/statistics-network\/explorer"},{"key":"3734_CR4","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s11845-022-02926-x","volume":"191","author":"D Courtney","year":"2022","unstructured":"Courtney, D. et al. Breast cancer recurrence: factors impacting occurrence and survival. Ir. J. Med Sci. 191, 2501\u20132510 (2022).","journal-title":"Ir. J. Med Sci."},{"key":"3734_CR5","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429\u20134434 (2007).","journal-title":"Clin. Cancer Res."},{"key":"3734_CR6","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/ijms22105123","volume":"22","author":"E Munari","year":"2021","unstructured":"Munari, E. et al. PD-1\/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. IJMS 22, 5123 (2021).","journal-title":"IJMS"},{"key":"3734_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3734_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3734_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann. Oncol. 32, 994\u20131004 (2021).","journal-title":"Ann. Oncol."},{"key":"3734_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jcp-2022-208637","volume":"77","author":"A Noske","year":"2024","unstructured":"Noske, A. et al. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens. J. Clin. Pathol. 77, 239\u2013245 (2024).","journal-title":"J. Clin. Pathol."},{"key":"3734_CR11","doi-asserted-by":"publisher","first-page":"v858","DOI":"10.1093\/annonc\/mdz394.009","volume":"30","author":"HS Rugo","year":"2019","unstructured":"Rugo, H. S. et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130. Ann. Oncol. 30, v858\u2013v859 (2019).","journal-title":"Ann. Oncol."},{"key":"3734_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/PAI.0000000000001062","volume":"30","author":"T Vlajnic","year":"2022","unstructured":"Vlajnic, T. et al. PD-L1 expression in triple-negative breast cancer\u2014a comparative study of 3 different antibodies. Appl. Immunohistochem. Mol. Morphol. 30, 726\u2013730 (2022).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"3734_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01724-2","volume":"25","author":"G Sigurjonsdottir","year":"2023","unstructured":"Sigurjonsdottir, G. et al. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms. Breast Cancer Res. 25, 123 (2023).","journal-title":"Breast Cancer Res."},{"key":"3734_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/PO.20.00412","volume":"5","author":"EA Prince","year":"2021","unstructured":"Prince, E. A., Sanzari, J. K., Pandya, D., Huron, D. & Edwards, R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis. Oncol. 5, 953\u2013973 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"3734_CR15","unstructured":"ESMO triple-negative breast cancer living guidelines. ESMO www.esmo.org\/living-guidelines\/esmo-metastatic-breast-cancer-living-guideline\/triple-negative-breast-cancer (2023)."},{"key":"3734_CR16","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: breast cancer version 2.2024. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/stage_iv_breast-patient.pdf (2024)."},{"key":"3734_CR17","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"3734_CR18","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3734_CR19","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819\u20131830 (2019).","journal-title":"Lancet"},{"key":"3734_CR20","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3734_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"3734_CR22","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2\u2013negative metastatic breast cancer. J. Clin. Oncol 28, 3239\u20133247 (2010).","journal-title":"J. Clin. Oncol"},{"key":"3734_CR23","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666\u20132676 (2007).","journal-title":"N. Engl. J. Med."},{"key":"3734_CR24","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert, N. J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252\u20131260 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3734_CR25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/jco.2010.28.15_suppl.1021","volume":"28","author":"A Brufsky","year":"2010","unstructured":"Brufsky, A. et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J. Clin. Oncol. 28, 1021 (2010).","journal-title":"J. Clin. Oncol."},{"key":"3734_CR26","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","volume":"24","author":"DW Miles","year":"2013","unstructured":"Miles, D. W. et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann. Oncol. 24, 2773\u20132780 (2013).","journal-title":"Ann. Oncol."},{"key":"3734_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3734_CR28","doi-asserted-by":"publisher","first-page":"598877","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack, S. P., Zhu, A. X. & Wang, Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities. Front. Immunol. 11, 598877 (2020).","journal-title":"Front. Immunol."},{"key":"3734_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13046-018-0999-5","volume":"38","author":"E Reguera-Nu\u00f1ez","year":"2019","unstructured":"Reguera-Nu\u00f1ez, E. et al. Therapeutic impact of Nintedanib with paclitaxel and\/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. J. Exp. Clin. Cancer Res. 38, 16 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"3734_CR30","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clin. Cancer Res. 26, 1712\u20131724 (2020).","journal-title":"Clin. Cancer Res."},{"key":"3734_CR31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","volume":"160","author":"T Oyama","year":"1998","unstructured":"Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160, 1224\u20131232 (1998).","journal-title":"J. Immunol."},{"key":"3734_CR32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel, S. et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071\u20131121 (2011).","journal-title":"Physiol. Rev."},{"key":"3734_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin, J. J. et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).","journal-title":"Nat. Commun."},{"key":"3734_CR34","doi-asserted-by":"publisher","first-page":"e7669","DOI":"10.1371\/journal.pone.0007669","volume":"4","author":"CL Roland","year":"2009","unstructured":"Roland, C. L. et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE 4, e7669 (2009).","journal-title":"PLoS ONE"},{"key":"3734_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","volume":"52","author":"PS Hegde","year":"2018","unstructured":"Hegde, P. S., Wallin, J. J. & Mancao, C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol. 52, 117\u2013124 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"3734_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01362-y","volume":"22","author":"M Quintela-Fandino","year":"2020","unstructured":"Quintela-Fandino, M. et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res. 22, 124 (2020).","journal-title":"Breast Cancer Res."},{"key":"3734_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","volume":"171","author":"Y Ozaki","year":"2022","unstructured":"Ozaki, Y. et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). Eur. J. Cancer 171, 193\u2013202 (2022).","journal-title":"Eur. J. Cancer"},{"key":"3734_CR38","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983\u2013993 (2021).","journal-title":"Ann. Oncol."},{"key":"3734_CR39","doi-asserted-by":"publisher","first-page":"e007959","DOI":"10.1136\/jitc-2023-007959","volume":"12","author":"X Li","year":"2024","unstructured":"Li, X. et al. Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1\/PD-L1 inhibitors. J. Immunother. Cancer 12, e007959 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"3734_CR40","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): An open-label, single-arm, phase II trial. Clin. Cancer Res. 28, 2807\u20132817 (2022).","journal-title":"Clin. Cancer Res."},{"key":"3734_CR41","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1016\/j.annonc.2024.08.295","volume":"35","author":"Q Ouyang","year":"2024","unstructured":"Ouyang, Q. et al. 347MO The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC). Ann. Oncol. 35, S360\u2013S361 (2024).","journal-title":"Ann. Oncol."},{"key":"3734_CR42","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1016\/j.annonc.2024.08.296","volume":"35","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. 348MO A phase Ib\/II study to assess the safety and efficacy of PM8002\/BNT327 in combination with nab-paclitaxel for first-line treatment of locally advanced or metastatic triple-negative breast cancer. Ann. Oncol. 35, S361 (2024).","journal-title":"Ann. Oncol."},{"key":"3734_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01536-6","volume":"21","author":"S-Y Wu","year":"2022","unstructured":"Wu, S.-Y. et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol. Cancer 21, 84 (2022).","journal-title":"Mol. Cancer"},{"key":"3734_CR44","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3734_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749\u2013757 (2018).","journal-title":"Nat. Med."},{"key":"3734_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02405-4","author":"A Oaknin","year":"2023","unstructured":"Oaknin, A. et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(23)02405-4 (2023).","journal-title":"Lancet"},{"key":"3734_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11368-2","volume":"23","author":"H Chen","year":"2023","unstructured":"Chen, H., Huang, F., Chen, Q. & Deng, Y. Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers. BMC Cancer 23, 841 (2023).","journal-title":"BMC Cancer"},{"key":"3734_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med."},{"key":"3734_CR49","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med."},{"key":"3734_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00448-4","volume":"8","author":"R Yoder","year":"2022","unstructured":"Yoder, R. et al. Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. NPJ Breast Cancer 8, 80 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"3734_CR51","first-page":"1","volume":"9","author":"P Schmid","year":"2024","unstructured":"Schmid, P. 181O \u2013 Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). Ann. Oncol. 9, 1\u201347 (2024).","journal-title":"Ann. Oncol."},{"key":"3734_CR52","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","volume":"34","author":"P Schmid","year":"2023","unstructured":"Schmid, P. et al. 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Updated results from BEGONIA, a phase Ib\/II study. Ann. Oncol. 34, S337 (2023).","journal-title":"Ann. Oncol."},{"key":"3734_CR53","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.annonc.2022.03.185","volume":"33","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from BEGONIA, a phase Ib\/II study. Ann. Oncol. 33, S199 (2022).","journal-title":"Ann. Oncol."},{"key":"3734_CR54","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline update. J. Clin. Oncol. 38, 1346\u20131366 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3734_CR55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline update. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.22.02864 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3734_CR56","doi-asserted-by":"publisher","first-page":"1048242","DOI":"10.3389\/fonc.2023.1048242","volume":"13","author":"M Sampayo-Cordero","year":"2023","unstructured":"Sampayo-Cordero, M. et al. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer. Front. Oncol. 13, 1048242 (2023).","journal-title":"Front. Oncol."},{"key":"3734_CR57","doi-asserted-by":"crossref","unstructured":"Jung, S.-H. Randomized Phase II Cancer Clinical Trials (Chapman and Hall\/CRC, 2013).","DOI":"10.1201\/b14751"},{"key":"3734_CR58","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","volume":"8","author":"WM Hryniuk","year":"1990","unstructured":"Hryniuk, W. M. & Goodyear, M. The calculation of received dose intensity. J. Clin. Oncol. 8, 1935\u20131937 (1990).","journal-title":"J. Clin. Oncol."},{"key":"3734_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers, H. & Reiser, M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit. Rev. Oncol. Hematol. 77, 221\u2013240 (2011).","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03734-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03734-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03734-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:06:37Z","timestamp":1757174797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03734-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3734"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03734-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.G. reports having received honoraria from Novartis, Gilead, AstraZeneca and Pfizer; having personal support for attending meetings and\/or travel from Roche, Pfizer, AstraZeneca and Gilead; and having received honoraria for advisory board participation from Gilead, Novartis, AstraZeneca and Pfizer. I.B. reports having received honoraria as Medical Monitor from MEDSIR; having received honoraria for advisory board participation from AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Gilead, Gr\u00fcnenthal, GSK, Jazz Pharmaceutical, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen and Veracyte; having personal support for attending meetings and\/or travel from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer, Pierre-Fabre and Roche; and having received institutional financial support from Agendia, AstraZeneca, Lilly, Pfizer and Roche. A.C.-S. reports having received personal honoraria for advisory board participation from GlaxoSmithKline and AstraZeneca; having personal honoraria for speakers\u2019 bureaus from GlaxoSmithKline, AstraZeneca, MSD, Eisai, Accord Healthcare, Pfizer, and Pharma&; having personal support for attending meetings and\/or travel from Pfizer, GlaxoSmithKline and MSD. They are also founder of ONCARE Madrid. F.M. reports having consulting fees from AstraZeneca, Clovis, Daiichi Sankyo, EISAI, Gilead, GlaxoSmithKline, Novartis, Myriad Genetic, Seagen, Stemline Menarini, Lilly, MSD, Pfizer, Roche, Bionteck and Nerviano; having personal honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for AstraZeneca, Clovis, Daiichi Sankyo, EISAI, Gilead, GlaxoSmithKline, Myriad Genetic, Seagen, Stemline Menarini, Lilly, MSD, Pfizer and Roche; having personal support for attending meetings and\/or travel from AstraZeneca, Daiichi Sankyo, Gilead, GlaxoSmithKline, Stemline Menarini, Lilly, Pfizer and Roche; and having received honoraria for advisory board participation from Immutep, Amgen and Palleos. S.M. has received personal support for attending meetings and\/or travel from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, MSD and Pfizer; and has received institutional financial support from Lilly. I.C.-P. reports having received personal honoraria as consultant, advisor and speaker from Gilead, MSD, Roche and AstraZeneca; having received personal honoraria for educational events from Roche and Daiichi Sankyo; and having received institutional financial support from Roche. S.R. reports having personal honoraria for speakers\u2019 bureaus from Roche; and having personal support for attending meetings and\/or travel from Accord Healthcare and Lilly. A.M.-B. reports having personal support for attending meetings and\/or travel from GlaxoSmithKline, MSD and Roche; having received personal honoraria for speaker participation from AstraZeneca, GlaxoSmithKline and Seagen; and has received institutional financial support from GlaxoSmithKline. E.L. reports having received personal honoraria from Pfizer, Lilly, Novartis, Gilead, Daichii and AstraZeneca; and having received personal honoraria for advisory board participation from Gilead and Daichii. M.T.T. reports having received honoraria for local meetings from AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Gilead, Gr\u00fcnenthal, GlaxoSmithKline, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre and Roche; and having personal support for attending meetings and\/or travel from Merck, Pzifer and Servier. M. de L. reports having received honoraria for lectures, presentations, speakers bureaus, manuscript writing and educational events from Eli Lilly, Novartis, Seagen, Takeda, Roche, Daiichi Sankyo, Tomalab, Gilead, Genetic, Menarini, Sophos and Istituto Gentili; having received economical support for attending meetings and\/or travel from Gilead, Novartis, Roche and AstraZeneca; and having participated on a Data Safety Monitoring Board or Advisory Board for Pfizer, AstraZeneca, Sanofi, Seagen, Novartis, Ipsen, Roche, Pierre-Fabre, Daiichi Sankyo, GSK, MSD and Menarini. S.G.-V., J.A.G., O.B., J.R.-M. and M.S.-C. are full-time employees at MEDSIR. G.A. reports having personal support for attending meetings and\/or travel along with personal honoraria from MEDSIR. J.M.P.-G. reports having received personal honoraria for advisory board participation from Lilly, Roche, Eisai, Daichii Sankyo, AstraZeneca, Seattle Genetics, MSD and Gilead; having personal support for attending meetings and\/or travel from Roche; and being an employee at MEDSIR. J.C. reports being a consultant\/advisor for Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma, Delcath Systems, Inc., Hexagon Bio; receiving honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp & Dohme, Astrazeneca, Gilead, Steamline Therapeutics and Daiichi Sankyo; has stock of MAJ3 Capital and Leuko (relative); received travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead Merck Sharp & Dhome, Steamline Therapeutics; and has the following patents: Pharmaceutical Combinations of A Pi3k Inhibitor and a Microtubule Destabilizing Agent. Javier Cort\u00e9s Cast\u00e1n, Alejandro Piris Gim\u00e9nez, Violeta Serra Elizalde. WO 2014\/199294A\u2014Issued, Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cort\u00e9s.US 2019\/ 0338368 A1\u2014Licensed. J.C. also reports their institution received research funding from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London. A.L.-C. reports receiving research support from Roche, Agendia, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Gilead and Daichii-Sanyo; consulting or advisory role for Lilly, Roche, Pfizer and Novartis; speakers\u2019 bureaus from Lilly, AstraZeneca, Pfizer, Novartis and Merck Sharp & Dohme; travel support from Roche, Pfizer, Steamline Therapeutics, Merck Sharp & Dhome and AstraZeneca; and stock or other ownership of MAJ3 Capital and Initia-Research. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}